Keywords: Biogen Idec, Portola Pharma, Rheumatoid arthritis, Lupus, SLE, Syk inhibitors
Biogen Idec in up to $553 million deal with Portola for oral Syk inhibitor program
Article | 28 October 2011
USA-based Biogen Idec (Nasdaq: BIIB) and Portola Pharmaceutical have entered into an exclusive, worldwide collaboration and license agreement under which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
